Aberrant FAK signaling is associated with pathological conditions, e.g. the development of some cancers [31,32], and one experimental strategy to perturb FAK signaling is exogenous expression of the C-terminal non-catalytic domain, which functions as a dominant negative mutant [33-35]. This evidence concerns the gene PTK2 and cancer.